1) Welcome to our new #accredited#tweetorial on risk stratification to identify the patient with #T2D and #DKD most at risk for rapid progression to advanced CKD. I am Christos Argyropoulos MD, PhD (@ChristosArgyrop), Division Chief, Nephrology, @UNMHSC.
2) This #accredited#tweetorial series on #kidneydisease#DKD through the lens of #T2D is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance and is intended for healthcare providers.
4) Let's start with a case!
Your 1st clinic appointment is a 68♀️ with long standing (15 years) Type 2 Diabetes (#T2D), complicated by retinopathy and Chronic Kidney Disease (#CKD). Her most recent laboratory data were obtained 3 months & 2 weeks prior to this visit:
5)
✔️estimated Glomerular Filtration Rate (eGFR) of 45, 52 ml/min/1.73m2
✔️Urine Albumin to Creatinine Ratio, UACR of 350 & 650 mg/g.
The patient is on Lisinopril 20mg/d, Rosuvastatin 20 mg & amlodipine 10mg. She asks you about her risk for further #CKD progression:
6) Before diving in the answer, let's define the risk factors for developing #CKD in patients with #T2D.
These have been defined as susceptibility, initiation & progression factors that affect hemodynamic, metabolic, inflammatory & fibrotic pathways
🔓doi.org/10.2215/CJN.11…
7) A conceptual model for the development of #CKD has been put forward based on observations in patients with Type 1 Diabetes. The timeline and the progression of events are less well delineated & the pattern not so clearcut in patients with #T2D 🔓doi.org/10.1016/j.kint…
9) While 60% of patients did not develop albuminuria during UKDPS , once *any* albuminuria developed, rates of events (whether death or progression of #CKD) were higher than those before the development of albuminuria.
👉Albuminuria is a major risk factor in #T2D
10) How should we assess albuminuria & integrate this lab test into our clinical risk assessment?
It all starts with a simple measurement!
👉Measurement of the urine albumin-to-creatinine ratio (#UACR) in an untimed urinary sample is the preferred screening strategy in #T2D
11) There are various ways to detect the presence of albuminuria & different clinical cutoffs that have been proposed to grade its severity.
The current laboratory 🔓academic.oup.com/clinchem/artic… & @goKDIGO 🔓kdigo.org/wp-content/upl… guidelines provide a handy ref for assays & cutoffs
12) Practice Points:
✔️ Prefer a quantitative over a dipstick test
✔️If a patient who has had previously normal values, develops UACR >30mg/g, the test should be repeated 2x over a 3-6mo period
✔️UACR 30-300mg/g ➡️moderate albuminuria
✔️UACR > 300 mg/g ➡️ severe proteinuria
13) How did we come with the recommendation to examine #UACR in an untimed First Morning Void (FMV) sample? Let’s nerd out with #RENAAL, one of the two trials that made Angiotensin Receptor Blockers (#ARBs) standard of care for #CKD in #T2D 🔓nejm.org/doi/full/10.10….
14) Data from the 701 participants in RENAAL were used to probe the predictive ability of different measures of proteinuria
🔓jasn.asnjournals.org/content/21/8/1…
✔️ (U)ACR in FMV
✔️Urine Albumin Concentration in FMV
✔️24hr Urine Albumin Excretion (UAE)
✔️24hr Urine Protein Excretion (UPE)
15) Key findings from this paper:
➡️ UACR (continuous and as quintiles) had the highest standardized hazard ratio for doubling serum creatinine (DSC, loss of ~50% kidney function) or End Stage Kidney (Renal) Disease #ESRD#ESKD
➡️ UACR had the highest AUC to predict #ESKD, DSC
16) RENAAL is not the only study that has linked measures of proteinuria/albuminuria with #CKD progression and #ESKD in patients with depressed eGFR. Enter the CRIC (Chronic Renal Insufficiency Cohort) Study: 🔓pubmed.ncbi.nlm.nih.gov/29784612/
👉Albuminuria determined BOTH outcomes
17) Using guideline & clinically relevant cutoffs of albuminuria (<30, 30-299, 300-999, >1,000mg/d):
✔️#ESKD rates were 7.4, 34.8, 78.7, 178.7 per 1,000 person-years (PYs)
✔️#CKD progression rates were 17.0, 61.4, 130.5, 295.1 per 1,000 PYs
✔️Loss of eGFR also tracked albuminuria
18) While the previous studies examined the baseline albuminuria as predictor of risk, the more relevant scenario for clinical practice is one in which multiple measurements of eGFR & baseline albuminuria are available for dynamic risk assessment about #CKD progression.
20) To sum up:
✔️Albuminuria (preferably measured as a FMV UACR) is a continuous measure of risk for #CKD progression among pts w/ #T2D
✔️Risk is particularly high for UACR > 300mg/g
✔️ eGFR (& changes in eGFR) are also associated with progression risk
It is now time to …
21) ... return to the patient from our clinical vignette, and use the @goKDIGO guideline "heatmap" kdigo.org/wp-content/upl… to assess her risk.
Her eGFR is between 45-60 ml/min/1.73m2 & UACR > 300mg/gm, thus putting her at VERY HIGH risk for #CKD progression (X in the chart).
22) Similar heatmaps also apply to the other risks associated with #CKD:
✔️All-cause Death
✔️Cardiovascular Death
✔️Progression of #CKD
✔️#ESKD/#ESRD
✔️Acute Kidney Injury
🔓kidney-international.org/article/S0085-…
But nowadays we can go beyond such semiquantitative risk stratification!
23) The Kidney Risk Failure Equation (#KRFE) were developed in patients with #CKD stages G3-5 in Canada (thanks @NavTangri) & subsequently validated in more than 700k patients from 30+ countries.
Available in smartphone apps (e.g. @QxMD) and the web kidneyfailurerisk.com
24) There are two versions of this risk calculator:
➡️4 Variable: Age, Sex, eGFR, UACR
➡️8 Variable. Which of the following is NOT one of the additional 4 variables in the 8-variable model?
27) Back to yesterday's closing poll. Scroll⬆️and COMMIT if you haven't already! The 8⃣-variable version of the Kidney Risk Failure Equation (#KRFE) includes 4 Variable + Calcium, Phosphorus, Bicarbonate, & *Serum* Albumin
28) ✔️Both formulas include an adjustment for geography
✔️ 8V formula may discriminate better
🔓jamanetwork.com/journals/jama/…
29) The KRFE quantifies the risk for our patient & allows us to discuss the next steps for managing her risk
✔️referral to Nephrology as her 5 year risk is > 3%
✔️team based care (if the 2 year risk > 10%)
✔️preparation for renal replacement (if the 2 year risk > 20%)
30) Having a number helps our patients understand their risks. But we can also use this number to *reduce* their risk. In this case (68👩🦳, with eGFR of 45 & UACR ~500mg/g), proteinuria is the only modifiable risk factor. If the latter were to ⬇️ 100mg/g, the KFRE yields:
32) What did these re-analyses of RENAAL, IDNT, OVERT show?
✔️Changes in albuminuria in the first 6mo of therapy predict long term response:
👉⬇️albuminuria by 50% ➡️⬇️#ESKD by 45%
👉risk⬇️ was continuously related to albuminuria⬇️
✔️risk highest in those with highest UACR
33) Upon reviewing the patient's chart, you find that the patient has never been prescribed > 20 mg of Lisinopril. The patient also has history of Acute Kidney Injury (#AKI) during a hospitalization for sepsis. Which of the following is true about her #CKD progression risk?
34) AKI, low eGFR & Albuminuria are ALL predictors of #CKD progression
🔓diabetesjournals.org/care/article/3…
✔️AKI⬆️risk by 247%
✔️Albuminuria⬆️risk by 423%
✔️⬇️eGFR by 10 ml/min/1.73m2⬆️risk by 22%
Maladaptive responses inside the kidney underline this nexus
🔓ncbi.nlm.nih.gov/labs/pmc/artic…
35) The dose of the background Inhibitor of the Renin Angiotensin System (#RASi) is an important predictor of #CKD progression.
The relevant preclinical observations were made >25 years ago: maximizing any RASi decreased production of fibrotic factors
🔓kidney-international.org/article/S0085-…
36) The Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: effects of individualized maximization of ACEi or #ARB doses on #CKD progression & #ESKD.
Titration
👉risk⬇️by ~50%
👉proteinuria⬇️by ~20%
👉slower eGFR loss
👉no⬆️effect on BP
🔓jasn.asnjournals.org/content/18/6/1…
37) In meta-analyses, individualized maximization of the dose of the ACEi or ARB is associated with 22% ⬇️mortality in patients with #T2D against standard doses. cochranelibrary.com/cdsr/doi/10.10…
38) Wrapping up the case of our patient w/ #T2D, she is at high risk for #CKD progression because of:
✔️residual albuminuria
✔️low eGFR
✔️submaximal dose of lisinopril
✔️prior AKI
What if albuminuria persists after⬆️lisinopril or if the patient can't tolerate the higher dose?
39) Patients with residual albuminuria while maxed on an inhibitor of the Renin Angiotensin System need additional therapies to⬇️their increased #CKD progression risk.
Which class of drugs have NOT yet been approved by @US_FDA for nephroprotection for such patients?
40) To date, #SGLT2i#flozins (#canagliflozin and #dapagliflozin) and novel, nonsteroidal #MRAs (#finerenone) have been approved as nephroprotective agents by enrolling patients with residual albuminuria, depressed eGFR on maximally tolerate doses of ACEis/ARBs.
41) Despite the high baseline renal risk (pts were albuminuric on maxed ACEi/ARB), #SGLT2i & nonsteroidal #MRA materially⬇️the risk for
✔️#CKD progression
✔️#ESKD
✔️#cardiovascular mortality
✔️hospitalization for heart failure @Nephjc for maintaining the visual abstracts!
42) Take-home Points 1⃣:
💡Albuminuria (pre therapy, or residual after initiation of inhibitors of the Renin Angiotensin system) predicts risk for #CKD progression in pts w/ #T2D
✔️risk tools (KDIGO heatmap/KRFE) to visualize & quantitate risk when communicating with patients
43) Take-home Points 2⃣:
✔️Albuminuria (UACR in FMV) in pts before & after initiating tx w/ inhibitors of the Renin Angiotensin System
👉Patients w/ residual albuminuria after maxing RASi need further therapy to⬇️#CKD risk: #SGLT2i/#flozin & nonsteroidal MRA (finerenone)
Join us tomorrow for the launch of a new accredited tweetorial – a case-based program on the assessment and management of patients with IgA #nephropathy (#IgAN). Free CE/#CME for #physicians, #nurses, #pharmacists! Expert author none other than @IgAN_JBarratt. FOLLOW US . . .
2) This #accredited#tweetorial series on #kidneydisease#DKD through the lens of #T2D is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance and is intended for healthcare providers.
1) Welcome to a new #accredited#tweetorial on currently available treatments for mineralocorticoid receptor (MR) antagonism (#MRA), the differences among them, and how these differences impact on treatment of cardio-reno-metabolic diseases #CaReMe#FOAMed
2) Our expert author is Dr. Patrick Holmes MB BS, MSc, DipTher, MRCGP (@drpatrickholmes), a GP Partner at St. George’s Medical Practice, Darlington for 23 years. He is a Trustee for the Primary Care Diabetes Society and is Associate Editor for Diabetic Medicine @diabeticmed.
3) This program is supported by an educational grant from Bayer & is intended for #healthcare providers. Author disclosures can be found at ckd-ce.com/disclosures/. Prior programs, still available for CE/#CME credit, are at ckd-ce.com. CE/#CME credit 🇬🇧🇪🇺🇨🇦🇺🇸
(1) Welcome to this #accredited#tweetorial, on recent & emerging data on finerenone, a non-steroidal mineralocorticoid receptor antagonist. We’ll discuss what it is, what evidence supports its use, & where it might fit into future #renal guidelines. I am @drkevinfernando.
(2) This program is supported by an educational grant from Bayer and is intended for #healthcare providers. Author disclosures can be found at ckd-ce.com/disclosures/. Prior programs, still available for CE/#CME credit, are at ckd-ce.com.
(3) Let's start with a knowledge check.
The following therapeutic options have demonstrated a significant reduction in the progression of both #CKD and #cardiovascular mortality in people living with #T2D: 1. ACEi's & ARBs 2. Spironolactone 3. SGLT2 inhibitors 4. Finerenone
1) Welcome to a new #accredited#tweetorial on the #goKDIGO guidance regarding evaluation and management of focal segmental glomerulosclerosis (#FSGS)--one of the most common causes of primary glomerular disease in adults. Leading us through this material is @edgarvlermamd.
3) This educational program is supported by grants from Travere, Bayer, & Otsuka, and is intended for healthcare providers. Faculty disclosures can be found at ckd-ce.com/disclosures/. Past programs, still available for CE/#CME credit, are at ckd-ce.com.
Be sure to join us TOMORROW here on @ckd_ce for our first ORIGINAL accredited content . . . from none other than @edgarvlermamd . . . whom you #kidney-oriented clinicians will know as a comforting and familiar presence and as an AWESOME teacher. He'll be talking about ...